These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24378322)

  • 1. MTP gene polymorphisms and postprandial lipemia in familial combined hyperlipidemia: effects of treatment with atorvastatin.
    Klop B; Verseyden C; Ribalta J; Salazar J; Masana L; Cabezas MC
    Clin Investig Arterioscler; 2014; 26(2):49-57. PubMed ID: 24378322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atorvastatin on the clearance of triglyceride-rich lipoproteins in familial combined hyperlipidemia.
    Castro Cabezas M; Verseyden C; Meijssen S; Jansen H; Erkelens DW
    J Clin Endocrinol Metab; 2004 Dec; 89(12):5972-80. PubMed ID: 15579746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides.
    Castro Cabezas M; Erkelens DW; Kock LA; De Bruin TW
    Eur J Clin Invest; 1994 Oct; 24(10):669-78. PubMed ID: 7851467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of atorvastatin on fasting plasma and marginated apolipoproteins B48 and B100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemia.
    Verseyden C; Meijssen S; Cabezas MC
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5021-9. PubMed ID: 15472200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
    Boquist S; Karpe F; Danell-Toverud K; Hamsten A
    Atherosclerosis; 2002 May; 162(1):163-70. PubMed ID: 11947910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia.
    García-García AB; González C; Real JT; Martín de Llano JJ; González-Albert V; Civera M; Chaves FJ; Ascaso JF; Carmena R
    Pharmacogenet Genomics; 2005 Apr; 15(4):211-8. PubMed ID: 15864113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triglyceride-lowering effect of pitavastatin in a guinea pig model of postprandial lipemia.
    Aoki T; Yamazaki H; Tamaki T; Sato F; Kitahara M; Saito Y
    Arzneimittelforschung; 2003; 53(3):154-8. PubMed ID: 12705169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia.
    Guerin M; Egger P; Le Goff W; Soudant C; Dupuis R; Chapman MJ
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4991-5000. PubMed ID: 12414863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia.
    Lee SH; Park S; Kang SM; Jang Y; Chung N; Choi D
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):65-71. PubMed ID: 21386036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease.
    Dane-Stewart CA; Watts GF; Pal S; Chan D; Thompson P; Hung J; Mamo JC
    Metabolism; 2003 Oct; 52(10):1279-86. PubMed ID: 14564679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia.
    Verseyden C; Meijssen S; van Dijk H; Jansen H; Castro Cabezas M
    J Lipid Res; 2003 Nov; 44(11):2100-8. PubMed ID: 12923226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia.
    Nordøy A; Svensson B; Hansen JB
    J Thromb Haemost; 2003 Apr; 1(4):690-7. PubMed ID: 12871402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?
    Battula SB; Fitzsimons O; Moreno S; Owens D; Collins P; Johnson A; Tomkin GH
    Metabolism; 2000 Aug; 49(8):1049-54. PubMed ID: 10954025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocyte gene-expression profile in men with familial combined hyperlipidemia and its modification by atorvastatin treatment.
    Llaverias G; Pou J; Ros E; Zambón D; Cofán M; Sánchez A; Vázquez-Carrera M; Sánchez RM; Laguna JC; Alegret M
    Pharmacogenomics; 2008 Aug; 9(8):1035-54. PubMed ID: 18681780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postprandial plasma ApoB-48 levels are influenced by a polymorphism in the promoter of the microsomal triglyceride transfer protein gene.
    Lundahl B; Hamsten A; Karpe F
    Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):289-93. PubMed ID: 11834530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
    Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
    Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment.
    García-Otín AL; Civeira F; Aristegui R; Díaz C; Recalde D; Sol JM; Masramon X; Hernández G; Pocoví M;
    Eur J Clin Invest; 2002 Jun; 32(6):421-8. PubMed ID: 12059987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsomal triglyceride transfer protein -493T variant reduces IDL plus LDL apoB production and the plasma concentration of large LDL particles.
    Lundahl B; Skoglund-Andersson C; Caslake M; Bedford D; Stewart P; Hamsten A; Packard CJ; Karpe F
    Am J Physiol Endocrinol Metab; 2006 Apr; 290(4):E739-45. PubMed ID: 16291571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia.
    Nordøy A; Hansen JB; Brox J; Svensson B
    Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):7-16. PubMed ID: 11383326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.